Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $174.0 million.

  • Gsk's Long-Term Investments rose 6535.7% to $174.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.0 million, marking a year-over-year increase of 6535.7%. This contributed to the annual value of $122.7 million for FY2024, which is 9132.29% down from last year.
  • Per Gsk's latest filing, its Long-Term Investments stood at $174.0 million for Q3 2025, which was up 6535.7% from $117.4 million recorded in Q2 2025.
  • Gsk's 5-year Long-Term Investments high stood at $2.9 billion for Q4 2021, and its period low was -$1.4 million during Q3 2021.
  • In the last 5 years, Gsk's Long-Term Investments had a median value of $106.2 million in 2021 and averaged $413.2 million.
  • Over the last 5 years, Gsk's Long-Term Investments had its largest YoY gain of 3990143.64% in 2021, and its largest YoY loss of 10026.98% in 2021.
  • Gsk's Long-Term Investments (Quarter) stood at $2.9 billion in 2021, then plummeted by 39.96% to $1.7 billion in 2022, then fell by 17.99% to $1.4 billion in 2023, then crashed by 91.27% to $123.2 million in 2024, then soared by 41.24% to $174.0 million in 2025.
  • Its Long-Term Investments stands at $174.0 million for Q3 2025, versus $117.4 million for Q2 2025 and $124.7 million for Q1 2025.